SCHEDULE: Eventide Asset Management Discloses 5.9% Stake in Collegium

Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, reported a 5.9% beneficial ownership stake in Collegium Pharmaceuticals, Inc. as of December 31, 2025.

Summary

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John collectively reported beneficial ownership of 1,876,239 shares of Collegium Pharmaceuticals, Inc. common stock.
• This represents 5.9% of the outstanding class of securities.
• Eventide Asset Management, LLC holds sole voting and dispositive power over all 1,876,239 shares.
• Finny Kuruvilla and Robin C. John share voting and dispositive power over the same 1,876,239 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Eventide Asset Management, LLC acts as an investment adviser to various funds (Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Small Cap ETF) and separately managed accounts, none of which individually held more than 5% of Collegium's outstanding common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it confirms a significant institutional investment in Collegium Pharmaceuticals, suggesting investor confidence without indicating any activist intent or negative sentiment.

Positives

• A significant institutional investor, Eventide Asset Management, LLC, has disclosed a 5.9% beneficial ownership stake, indicating a notable investment in Collegium Pharmaceuticals, Inc.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by an institutional investor like Eventide Asset Management in a pharmaceutical company such as Collegium Pharmaceuticals can signal confidence in the company's long-term prospects within the specialized pain management and addiction treatment market. Such filings are routine for large asset managers and typically reflect portfolio allocation decisions rather than specific strategic moves related to the issuer.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder may provide a degree of confidence in the company's stock, potentially attracting further investor interest.
• Company Management: Awareness of a large institutional holder may influence management's strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of beneficial ownership by an institutional investor and does not contain new information regarding Collegium Pharmaceuticals' operational performance, financial health, or strategic direction. While the presence of a significant institutional holder like Eventide Asset Management can be a positive signal of long-term confidence, the filing itself does not provide a basis for a "buy" or "sell" recommendation. Therefore, a "hold" recommendation is appropriate, pending further fundamental analysis of the company's business and financial results.

Keywords

Collegium Pharmaceuticals, Eventide Asset Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Pharmaceuticals, Investment Adviser, COLX